Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term remission and monocyclic course in Still's disease patients starting canakinumab early: data from the international AIDA network registry.

Seminars in arthritis and rheumatism·2026
Same author

A rapid, accessible real-time PCR approach to identify UBA1 somatic mutations in VEXAS syndrome.

Frontiers in medicine·2026
Same author

Coevolution of NK and Tumor Cell States Along Multiple Myeloma Progression from Precursor Conditions.

International journal of molecular sciences·2026
Same author

Clinical associations and related factors of metabolic syndrome in systemic sclerosis: results from an observational multicenter study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale).

Rheumatology international·2026
Same author

Real-world damage accrual in Sjögren's disease: a 5-year multicentre GIRRCS cohort analysis.

RMD open·2026
Same author

Application of machine learning techniques to explore the occurrence of macrophage activation syndrome in Still's disease: results from the GIRRCS AOSD Study Group and the AIDA Network Still's Disease Registry.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jun 16, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Gammadelta T cell modulation in anticancer treatment.

Nadia Caccamo1, Francesco Dieli, Serena Meraviglia

  • 1Dipartimento di Biopatologia e Metodologie Biomediche, Università di Palermo, Palermo, Italy. caccamo@unipa.it

Current Cancer Drug Targets
|January 22, 2010
PubMed
Summary
This summary is machine-generated.

Vgamma9Vdelta2 T cells show promise in fighting infections and tumors. New drugs activate these cells, paving the way for innovative gammadelta T cell-based cancer immunotherapies currently in clinical trials.

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Related Experiment Videos

Last Updated: Jun 16, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Vgamma9Vdelta2 T cells possess broad antimicrobial and antitumoral activities.
  • These cells are crucial for immune control of infections and cancers, producing inflammatory cytokines and exhibiting cytolytic functions.
  • Activation by phosphoantigens offers potential for gammadelta T cell-based immunotherapies.

Purpose of the Study:

  • To review recent advances in the activation and expansion of gammadelta T cells.
  • To highlight the potential of these cells as a target for novel cancer immunotherapies.
  • To discuss the development of small drugs that selectively activate Vgamma9Vdelta2 T lymphocytes.

Main Methods:

  • Focus on in vitro and in vivo methods for gammadelta T cell activation and expansion.
  • Review of clinical trials investigating phosphoantigen-activated Vgamma9Vdelta2 T lymphocytes.
  • Analysis of drugs that enhance phosphoantigen accumulation in stressed cells.

Main Results:

  • Vgamma9Vdelta2 T cells can be selectively activated by phosphoantigens and specific drugs.
  • Ongoing clinical trials explore direct drug bioactivity and adoptive cell therapies.
  • These approaches show promise for innovative immunotherapy in cancer patients.

Conclusions:

  • Advances in gammadelta T cell activation offer a promising target for novel cancer immunotherapies.
  • Pharmacological activation of Vgamma9Vdelta2 T cells represents a key strategy.
  • Further research and clinical trials are essential to realize the full potential of gammadelta T cell-based therapies.